Clinical Trial Update: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma [Phase 3]

View source ↗

Summary

This Phase 3 trial compares the combination of encorafenib (LGX818) plus binimetinib (MEK162) against vemurafenib monotherapy and encorafenib monotherapy in pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• MEKTOVI (BINIMETINIB)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Pfizer | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2021-07-12